Understanding the risks of acute respiratory failure in patients with hospital-onset sepsis
Official title: Treatment implications of heterogeneity in acute respiratory failure risk among patients with hospital-onset sepsis
Funded at University of Colorado Denver · NIH-11082526 · Data updated 2026-11-12
This study looks at how patients with hospital-onset sepsis might face different chances of developing breathing problems, and it aims to find better ways to treat those at higher risk so they can get the care they need to feel better.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $167,832 |
| NIH project number | 5K01HL169843-02 |
| Project ID | NIH-11082526 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with hospital-onset sepsis who are at risk of developing acute respiratory failure.
✕Less likely to help
Patients with community-onset sepsis or those not experiencing hospital-onset sepsis may not benefit from this research.
What this research studies
This research investigates how different patients with hospital-onset sepsis (HOS) experience varying risks of developing acute respiratory failure (ARF). By analyzing data from multiple hospitals, the study aims to identify specific characteristics and treatment responses among these patients. The goal is to develop tailored treatment strategies that improve outcomes by addressing the unique needs of individuals at high risk for ARF. This approach seeks to enhance the timing and effectiveness of interventions for vulnerable patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that significantly reduce the risk of acute respiratory failure in patients with hospital-onset sepsis.
How similar studies have gone: Preliminary studies have shown promising associations between treatment timing and outcomes in similar patient populations, indicating potential for success in this research.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Ginestra, Jennifer Claire — University of Colorado Denver
- Study coordinator: Ginestra, Jennifer Claire
Related research
Other NIH-funded projects on the same topics.
-
Understanding which patients and hospital care pathways affect outcomes after ICU vs ward care for ARF and sepsis
A big study using hospital records to figure out which patients with acute respiratory failure and sepsis do best when admitted to ICUs versus general wards.
-
Understanding how care decisions affect outcomes for patients with breathing problems and sepsis
This project looks at hospital records to understand how decisions about where patients with severe breathing issues and sepsis receive care affect their recovery.
-
Understanding why critically ill patients with respiratory failure and sepsis face health disparities.
This study is looking into why critically ill patients with breathing problems and infections, especially those from minority backgrounds, often have worse health outcomes, and it aims to find ways to improve their care based on their unique challenges.
-
Understanding how ICU and ward care affects patients with severe respiratory issues and sepsis
This study looks at how choosing to treat patients with serious breathing problems and infections in either intensive care units or regular hospital rooms affects their recovery, with the aim of finding ways to improve care for these patients.
-
Using Ganciclovir to Prevent Cytomegalovirus Reactivation in Patients with Severe Respiratory Issues
This study is looking at whether the antiviral medication ganciclovir can help prevent the reactivation of cytomegalovirus (CMV) in adults with severe respiratory failure caused by sepsis, to see if it can improve their recovery and reduce the time they spend on a ventilator and in the ICU.
-
Using ganciclovir to stop cytomegalovirus from reactivating in patients with severe respiratory failure and sepsis
This study is looking at whether the antiviral drug ganciclovir can help prevent a virus called cytomegalovirus (CMV) from coming back in adults who are seriously ill with respiratory failure from sepsis, and it’s for people who want to help improve treatment options for patients in critical condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.